Senesco Technologies is focused on the development of cancer therapeutics. The company’s platform technology is based on the discovery that eIF5A (Factor 5A) – a gene highly conserved from plants to people – is capable of regulating programmed cell death (apoptosis) and cell survival. Senesco has started a clinical program with lead therapeutic candidate SNS01-T in multiple myeloma patients. The company is also building its portfolio by investigating other potential eIF5A applications. For more information, visit the company’s Web site at www.senesco.com.
Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.
Let us hear your thoughts below: